查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965879

心臟生物標記市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Cardiac Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球心臟生物標記市場預計將從 2025 年的 184.1 億美元成長到 2031 年的 292.3 億美元，複合年成長率為 8.01%。

這些生物標記由心臟壓力期間釋放到血液中的可測量酵素和蛋白質組成，是診斷心肌梗塞等疾病的重要指標。該市場的成長主要受心血管疾病發病率上升以及緊急情況下快速準確診斷的迫切需求的驅動。大量疾病負擔數據凸顯了這項需求。根據美國心臟協會 (AHA) 估計，到 2024 年，約有 1.269 億美國成年人將患有某種形式的心血管疾病，如此高的盛行率需要進行廣泛的診斷檢測，從而持續推動市場收入成長。

市場概覽
預測期 2027-2031
市場規模：2025年 184.1億美元
市場規模：2031年 292.3億美元
複合年成長率：2026-2031年 8.01%
成長最快的細分市場 BillionP 和 NT-proBillionP
最大的市場 北美洲

然而，阻礙市場發展的一大障礙是新型診斷檢測套組嚴格的監管核准流程。製造商必須遵守複雜的合規標準，並經歷漫長的檢驗階段以證明其臨床效用，這增加了研發成本並延遲了產品上市。此外，國際醫療保健體系對新興生物標記的報銷覆蓋範圍不均，也會阻礙其商業性應用，並削弱新供應商檢測方案的財務永續性。

市場促進因素

全球心血管疾病盛行率的不斷上升是心臟生物標記市場的主要驅動力，從而持續推高了對診斷檢測的需求。隨著心臟衰竭和心肌梗塞等疾病發病率的增加，醫療機構越來越依賴高靈敏度的生物標記進行有效的風險分層和快速分流。日益加重的疾病負擔直接導致臨床和醫院環境中檢測量的增加，因此需要建立完善的診斷基礎設施。根據美國疾病管制與預防中心 (CDC) 於 2025 年 6 月發布的《關鍵統計快報》，2024 年美國心臟相關死亡人數將達到 683,037 人，這凸顯了精準檢測工具對於管理不斷成長的患者群體和預防嚴重後果的迫切需求。

同時，高靈敏度生物標記檢測技術的進步正在提高診斷準確性並擴大市場潛力。這些先進的解決方案能夠檢測到濃度較低的肌鈣蛋白，從而比傳統方法更早識別心肌損傷，進而推動預防性患者照護的發展。市場對這些創新技術的正面反應已在財務指標中得到體現。根據雅培公司2024年10月發布的2024年第三季財報，更新的診斷系統的普及推動了其全球核心實驗室診斷銷售額4.5%的內部成長。羅氏公司也強調了這一高容量應用趨勢，其報告稱，2025會計年度全球整體總合進行了300億次診斷測試。

市場挑戰

嚴格的監管核准流程是阻礙全球心臟生物標記市場擴張的一大障礙。製造商必須遵守複雜的合規要求，並經歷全面的檢驗階段，才能確立新型診斷檢測方法的臨床效用。這項嚴苛的核准流程延長了產品上市前的研發週期，並顯著增加了營運成本。因此，核准所需的大量時間和資金投入往往阻礙了企業推出創新型生物標記物，減緩了創新步伐，並限制了先進診斷解決方案的應用。

這些監管壓力帶來的後果在近期行業趨勢中得到了清晰的體現，即企業紛紛策略性地退出那些合規要求複雜的市場。根據歐洲醫療技術協會（MedTech Europe）2024年的數據，由於新的監管環境帶來的種種困難，選擇歐盟作為其首批產品上市主要市場的主要體外診斷試劑製造商的比例下降了40%。這項數據凸顯了繁重的監管要求如何迫使企業重新分配資源並推遲產品上市策略。這些阻礙必要診斷工具部署的監管壁壘，極大地限制了收入潛力，並限制了整個產業的商業性成長。

市場趨勢

隨著臨床檢查室致力於簡化工作流程以應對日益成長的檢測工作量，自動化高通量免疫檢測系統的興起正在從根本上改變全球心臟生物標記市場。製造商們不斷推出整合免疫診斷和臨床化學的平台，最大限度地減少人工操作，並縮短關鍵心臟檢測的周轉時間。對先進診斷基礎設施的強勁需求反映在近期的市場趨勢中。根據羅氏公司2025年1月發布的題為「羅氏公佈2024年強勁業績，銷售額成長7%」的新聞稿，該公司診斷部門的基礎業務銷售額（不計外匯波動的影響）成長了8%，這主要得益於免疫診斷解決方案的持續普及以及cobas質譜系統的實施。

同時，個人化醫療和以價值為導向的心臟照護模式的轉變正在重塑市場動態，要求醫療服務提供者實施能夠減少不必要資源消耗的診斷通訊協定。利用高精準度生物標記進行快速風險分層，能夠幫助醫院有效率地篩選出急性心臟疾病事件，進而緩解急診室的壅塞狀況，降低整體醫療成本。近期統計數據也印證了這項提升營運效率的趨勢。根據GlobalRPH於2025年10月發表的一篇報導《高敏肌鈣蛋白檢測：終結不必要的胸痛住院？ 》，高敏肌鈣蛋白I檢測通訊協定的實施使胸痛相關住院人數以金額為準減少了5.6%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球心臟生物標記市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（肌鈣蛋白、CK-MB、肌紅蛋白、BNP 和 NT-proBNP、其他）
    • 依應用領域（急性冠狀動脈症候群、心肌梗塞、鬱血性心臟衰竭等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美心臟生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲心臟生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區心臟生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲心臟生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲心臟生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球心臟生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Randox Laboratories Ltd.
  • Creative Diagnostics
  • Life Diagnostics Inc.
  • BIOMeRIEUX Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24326

The Global Cardiac Biomarkers Market is projected to expand from USD 18.41 Billion in 2025 to USD 29.23 Billion by 2031, registering a CAGR of 8.01%. These biomarkers, consisting of measurable enzymes or proteins released into the bloodstream during cardiac stress, function as vital indicators for diagnosing conditions such as myocardial infarction. The market is propelled chiefly by the increasing frequency of cardiovascular disorders and the urgent requirement for precise, rapid diagnostics in emergency scenarios. This necessity is highlighted by significant disease burden data; according to the American Heart Association, approximately 126.9 million adults in the United States were estimated to have a form of cardiovascular disease in 2024, a prevalence that necessitates widespread diagnostic testing and continuously drives market revenue.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 18.41 Billion
Market Size 2031USD 29.23 Billion
CAGR 2026-20318.01%
Fastest Growing SegmentBillionP and NT-proBillionP
Largest MarketNorth America

However, a major obstacle impeding market progression is the rigorous regulatory approval process mandated for new diagnostic assays. Manufacturers face the task of navigating intricate compliance standards and enduring prolonged validation phases to prove clinical utility, which escalates development costs and postpones product launches. Additionally, uneven reimbursement coverage for emerging biomarkers across international healthcare systems can hinder commercial uptake and curtail the financial sustainability of testing solutions for newer providers.

Market Driver

The rising global prevalence of cardiovascular diseases serves as a primary engine for the cardiac biomarkers market, generating consistent demand for diagnostic testing. With the incidence of conditions like heart failure and myocardial infarction increasing, medical providers are relying more heavily on sensitive biomarkers for effective risk stratification and rapid triage. This growing disease burden leads directly to elevated testing volumes in clinical and hospital environments, requiring a strong diagnostic infrastructure. According to the 'Vital Statistics Rapid Release' report by the Centers for Disease Control and Prevention in June 2025, heart disease-related deaths in the United States climbed to 683,037 in 2024, highlighting the essential need for precise tools to manage the expanding patient population and prevent severe outcomes.

Concurrently, technological advancements in high-sensitivity biomarker assays are broadening market potential by improving diagnostic accuracy. These sophisticated solutions enable the detection of cardiac troponin at much lower concentrations, allowing for the identification of myocardial injury significantly earlier than traditional methods, which supports a shift toward proactive patient care. The market's favorable reception of these innovations is evident in financial metrics; according to Abbott's 'Third-Quarter 2024 Results' press release from October 2024, global Core Laboratory Diagnostics sales grew by 4.5 percent organically, fueled by the uptake of updated diagnostic systems. Underscoring this trend of high-volume usage, Roche reported delivering a total of 30 billion diagnostic tests globally during the preceding fiscal year in 2025.

Market Challenge

The exacting regulatory approval process acts as a significant hurdle that directly impedes the expansion of the Global Cardiac Biomarkers Market. Manufacturers are required to maneuver through complex compliance structures and undertake comprehensive validation stages to establish the clinical utility of new diagnostic assays. This intense scrutiny results in extended development schedules and substantially increased operational expenses before a product can reach the commercial stage. Consequently, the substantial investment of time and capital needed to obtain approvals frequently discourages companies from launching innovative biomarkers, thereby slowing the rate of innovation and limiting the introduction of advanced diagnostic solutions.

The consequence of these regulatory pressures is visible in recent industry trends, where there is a strategic withdrawal from markets characterized by complicated compliance mandates. According to MedTech Europe in 2024, the preference for the European Union as the primary region for initial product launches by major in vitro diagnostic manufacturers fell by 40 percent due to difficulties linked to the new regulatory landscape. This data point emphasizes how burdensome regulatory requirements compel firms to reallocate resources and postpone launch strategies. By hindering the rollout of necessary diagnostic tools, these regulatory obstacles effectively limit revenue potential and restrict the sector's broader commercial growth.

Market Trends

The rise of Automated High-Throughput Immunoassay Systems is fundamentally transforming the Global Cardiac Biomarkers Market as clinical labs focus on workflow efficiency to handle growing testing loads. Manufacturers are increasingly releasing integrated platforms that merge immunodiagnostics with clinical chemistry, thereby minimizing manual tasks and accelerating turnaround times for essential cardiac assays. This strong demand for sophisticated diagnostic infrastructure is reflected in recent market performance; according to Roche's January 2025 press release titled 'Roche reports strong 2024 results with 7% sales growth,' the company's Diagnostics Division saw base business sales rise by 8 percent at constant exchange rates, driven by the continued adoption of immunodiagnostic solutions and the launch of the cobas Mass Spec system.

Simultaneously, a movement toward Personalized Medicine and Value-Based Cardiac Care is shaping market dynamics, urging healthcare providers to implement diagnostic protocols that reduce unnecessary resource use. By utilizing high-precision biomarkers for swift risk stratification, hospitals can efficiently rule out acute cardiac events, which helps alleviate emergency department congestion and lowers overall healthcare expenses. This trend toward enhanced operational efficiency is backed by recent statistics; according to a GlobalRPH article from October 2025 titled 'High-Sensitivity Troponin Testing: The End of Unnecessary Chest Pain Admissions?', the adoption of high-sensitivity cardiac troponin I testing protocols led to an absolute reduction of 5.6 percent in hospital admissions related to chest pain.

Key Market Players

  • Abbott Laboratories Inc.
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Randox Laboratories Ltd.
  • Creative Diagnostics
  • Life Diagnostics Inc.
  • BIOMeRIEUX Inc.

Report Scope

In this report, the Global Cardiac Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cardiac Biomarkers Market, By Type

  • Troponin
  • CK-MB
  • Myoglobin
  • BNP and NT-proBNP
  • Others

Cardiac Biomarkers Market, By Application

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Others

Cardiac Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cardiac Biomarkers Market.

Available Customizations:

Global Cardiac Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cardiac Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others)
    • 5.2.2. By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cardiac Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cardiac Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Cardiac Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Cardiac Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Cardiac Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cardiac Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Cardiac Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Cardiac Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Cardiac Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Cardiac Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Cardiac Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cardiac Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Cardiac Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Cardiac Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Cardiac Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Cardiac Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Cardiac Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cardiac Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Cardiac Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Cardiac Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Cardiac Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cardiac Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Cardiac Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Cardiac Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cardiac Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. QuidelOrtho Corporation
  • 15.3. Siemens Healthineers AG
  • 15.4. F. Hoffmann-La Roche Ltd
  • 15.5. Danaher Corporation
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Randox Laboratories Ltd.
  • 15.8. Creative Diagnostics
  • 15.9. Life Diagnostics Inc.
  • 15.10. BIOMeRIEUX Inc.

16. Strategic Recommendations

17. About Us & Disclaimer